Fig. 1 | Cell Death & Differentiation

Fig. 1

From: TC2N, a novel oncogene, accelerates tumor progression by suppressing p53 signaling pathway in lung cancer

Fig. 1The alternative text for this image may have been generated using AI.

The expression level of TC2N is correlated with lung cancer progression. a The measurements of TC2N expression in lung cancer cell lines compared with the normal cell line HBE by qRT-PCR and WB. ACTIN is shown as a loading control. The data were analyzed using the formula 2‒Δct. Data represent the mean ± SD of triplicates. b, c The protein expression of TC2N in adjacent and tumor lung samples monitored by immunohistochemistry (IHC) on a tissue array. The anti-TC2N antibody was employed for IHC. IHC scoring was performed blind, prior to association with clinical data. d IHC analysis on a tissue array of lung cancers at different histological grades. e Immunohistochemistry analysis on a tissue array of lung cancers at different clinical stages. Scale bars represent 50 μm. f Kaplan–Meier analysis of TC2N expression in 272 lung cancer patients subdivided into two groups. g Kaplan–Meier analysis of TC2N expression in 272 lung cancer patients subdivided into three groups *P < 0.05

Back to article page